Test Price
2,800 AED✅ Home Collection Available
TBR1 Gene Next-Generation Sequencing Test for Intellectual Disability in Dubai, UAE
Definitive molecular diagnosis for TBR1‑related neurodevelopmental disorders through comprehensive next‑generation sequencing, aligned with UAE healthcare standards.
Executive Summary & Core Metrics
Diagnostic Accuracy >99.9%
Gold‑standard NGS with ISO‑certified analytical validation for clinical confidence.
VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection
Available daily from 8 AM to 11 PM, hospital‑grade logistics with ISO‑certified transport.
Telephonic Post‑Test Genetic Counselling
Expert interpretation support for patients and referring physicians.
Insurance Verification via WhatsApp
Direct billing check: +971 54 548 8731
Price: 2,800 AED | Turnaround Time: 3 – 4 Weeks | Methodology: Next‑Generation Sequencing (NGS)
Test Overview & Methodology
The TBR1 Gene Next‑Generation Sequencing Test for Intellectual Disability is a comprehensive assay designed to detect pathogenic variants in the T‑box, brain 1 gene, a key regulator of cortical development. This test provides a definitive molecular diagnosis for individuals with unexplained intellectual disability, autism spectrum features, and related neurodevelopmental phenotypes. Whole blood, extracted DNA, or FTA card (dried blood spot) specimens are accepted and processed under ISO‑accredited laboratory conditions.
| Feature | NGS TBR1 Gene Test | Alternative Sanger Sequencing |
|---|---|---|
| Diagnostic Sensitivity | >99.9% (SNVs, indels, CNVs) | ~95–98% (limited to known coding regions) |
| Methodology | Next‑Generation Sequencing with full gene coverage | Exon‑by‑exon Sanger sequencing |
| Turnaround Time | 3 – 4 Weeks | 6 – 8 Weeks |
| Sample Types | Whole Blood, Extracted DNA, FTA Card (dried blood spot) | Whole Blood only |
| Regulatory Compliance | DHA/MOHAP approved, ISO 9001:2015, UAE PDPL | Limited local accreditation |
Physician Insight & Safety Protocols
“As a clinical geneticist, I understand the deep uncertainty families face when navigating intellectual disability. The TBR1 NGS test offers a precise molecular answer, yet every result must be interpreted within the full clinical and familial context. This tool guides diagnosis and genetic counselling, but it never replaces a comprehensive medical evaluation.”
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory Notice
Do not discontinue prescribed medications or alter treatment plans without consulting your physician. This test is intended for diagnostic clarification and genetic counselling, not as a standalone treatment decision tool. All pre‑test counselling must comply with the informed consent provisions of Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Inability to provide a blood sample (severe bleeding disorder, extreme vein fragility).
- Exclusion: Active systemic infection or sepsis at the time of intended collection.
- Emergency Red Flag: Sudden neurological deterioration, new‑onset seizures, or loss of consciousness requires immediate emergency evaluation, not elective genetic testing.
- Emergency Red Flag: Signs of raised intracranial pressure (persistent vomiting, severe headache, vision changes) – consult emergency services.
Patient FAQ & Clinical Guidance
1. What is the TBR1 gene NGS test and what does it detect?
The TBR1 gene NGS test detects disease‑causing mutations in the TBR1 gene, which is linked to intellectual disability and autism spectrum disorders. This advanced genetic screen analyzes the entire TBR1 gene using next‑generation sequencing, identifying pathogenic single nucleotide variants, small insertions/deletions, and copy number changes. It confirms a molecular diagnosis for patients with developmental delay, severe speech/language impairment, autistic features, and structural brain abnormalities.
2. How is the test performed and what is the turnaround time?
The test requires a simple blood draw (whole blood, extracted DNA, or dried blood spot on an FTA card). A certified phlebotomist can collect the sample at your home or at a partner clinic using temperature‑controlled cold‑chain logistics. DNA is extracted and processed in our ISO‑accredited laboratory. Results are delivered within 3 to 4 weeks from sample receipt, providing families with a reliable and relatively rapid path to molecular answers.
3. Do I need a referral or genetic counselling before taking the test?
Yes, UAE regulations mandate that any genetic test for intellectual disability be ordered by a qualified specialist, such as a clinical geneticist or neurologist. A dedicated pre‑test genetic counselling session is required to draw a pedigree chart, explain possible outcomes, and ensure informed consent. This process protects patients and families and aligns with Federal Decree‑Law No. 4 of 2016 on Medical Liability.
4. Does health insurance in the UAE cover the cost of this test?
Coverage varies by insurance network and plan. You can verify your coverage directly via WhatsApp at +971 54 548 8731. Our team provides immediate pre‑authorisation support and assists in submitting the required medical documentation to your insurer. We are committed to transparent billing and help navigate the approval process.
UAE Regulatory & Data Privacy Adherence
Data Privacy & Health Information Protection: All patient data is handled in strict compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols conform to Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Laboratory procedures are ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139) and fully comply with DHA and MOHAP standards.
Clinical & Logistical Metadata
| Test Name | TBR1 Gene Next‑Generation Sequencing Test for Intellectual Disability |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 – 4 Weeks |
| Sample Type / Matrix | Whole Blood, Extracted DNA, FTA Card (dried blood spot) |
| Methodology Used | Next‑Generation Sequencing (NGS) |
| ICD-10-CM Code | F78.9 |
| LOINC Code | 82370-6 |
| DHA Facility License & Laboratory Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians